Researchers at McMaster University have unveiled a surprising dual function for Growth Differentiation Factor 15 (GDF15), a naturally occurring hormone previously recognized primarily for its role in suppressing appetite and facilitating weight loss. The latest groundbreaking study, published in the esteemed journal Cell Metabolism on August 10, 2026, reveals that GDF15 possesses a potent, previously uncharacterized ability to shield the liver from inflammation and slow the progression of liver scarring, even in the absence of significant weight reduction. This discovery challenges the long-held paradigm that the hormone’s benefits are exclusively mediated through its impact on metabolic regulation and body mass, opening new avenues for therapeutic intervention in advanced fatty liver disease.
A New Frontier in Treating Advanced Fatty Liver Disease
Metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, affects millions globally and carries a significant risk of progressing to irreversible cirrhosis, liver cancer, and ultimately, liver failure. While the advent of novel weight-loss medications has offered a beacon of hope, improving outcomes for many patients, a critical challenge remains: persistent liver inflammation can endure even after substantial weight loss. This inflammation is a key driver of liver damage and fibrosis.
The McMaster study’s findings offer a potential breakthrough by identifying a distinct biological pathway that directly targets and suppresses this detrimental liver inflammation. This opens the door to the development of future therapies that could complement existing treatments focused on weight management and reducing liver fat, by directly addressing the inflammatory component of MASH.
“Our findings conclusively demonstrate that GDF15 performs a role far beyond merely regulating appetite and body weight,” stated Gregory Steinberg, a distinguished professor in McMaster University’s Department of Medicine and co-director of the Centre for Metabolism, Obesity and Diabetes Research (MODR), who served as the senior author of the study. “We have identified that GDF15 initiates a sophisticated signaling cascade from the brain to the liver, effectively suppressing inflammation and mitigating the development of fibrosis. This fundamentally alters our understanding of this hormone’s capabilities and suggests it may be an integral component of the body’s innate defense mechanisms against chronic liver injury.”
The Intricate Signaling Pathway: How GDF15 Shields the Liver
To meticulously investigate GDF15’s impact on advanced liver disease, the research team employed sophisticated mouse models meticulously engineered to mirror the complexities of human MASH. Through a comprehensive integration of genetic analysis, pharmacological interventions, genomic sequencing, and cutting-edge spatial transcriptomics techniques, the researchers were able to meticulously map the molecular events triggered by GDF15 activation.
The study revealed a remarkable brain-to-liver communication network. GDF15 initiates a signal originating in the brain, which is then transmitted via the nervous system. This neural signaling ultimately culminates in the release of glucocorticoids, a class of steroid hormones crucial for regulating metabolism, immune responses, and the body’s adaptation to stress. These glucocorticoids then act within the liver to dampen inflammatory processes.
Crucially, these protective effects were observed independently of any significant changes in food intake, body weight, or the accumulation of fat within the liver. Furthermore, GDF15 demonstrated an ability to decelerate the progression of liver fibrosis, the pathological scarring that characterizes the worsening stages of liver disease.
“Leveraging advanced spatial technologies, we observed that GDF15 plays a pivotal role in reprogramming liver cells, thereby reducing inflammation and the formation of scar tissue,” explained Dongdong Wang, the study’s first and corresponding author and an assistant professor in McMaster’s Department of Medicine. “Rather than exacerbating liver damage, GDF15 appears to actively modulate the liver’s immune system, shifting immune cells towards a more quiescent and protective state. This recalibration effectively reduces inflammation and safeguards the liver from further injury.”
GDF15: A Hormone of Two Surprising Functions
This latest discovery builds upon prior research conducted by Steinberg and Wang. A study published in 2023 had already indicated that GDF15 plays a vital role in helping the body preserve its metabolic rate, or calorie-burning capacity, during periods of weight loss. The current findings unveil a distinctly different, yet equally significant, function: the direct protection of the liver through an entirely novel anti-inflammatory pathway.
Collectively, these two studies provide a compelling foundation for the future development of targeted therapies aimed at specifically addressing liver inflammation, a critical and often intractable factor in the progression of MASH.
Professor Steinberg, who also holds executive membership in NexusHealth at McMaster and serves as chief scientific officer, shareholder, and co-founder of Espervita Therapeutics, has been actively engaged in preclinical research focused on potential therapeutic compounds for advanced liver disease. His recent co-authored work, published in Cell Metabolism (DOI: 10.1016/j.cmet.2025.11.015), describes a promising drug candidate. While that research explored an externally administered therapeutic, the current study illuminates a sophisticated biological pathway that the body naturally employs to combat liver inflammation, offering invaluable insights for guiding the design of future treatments.
A Synergistic Approach: Combining Weight Loss with Inflammation Control
The implications of this research are profound for the clinical management of MASH. Current therapeutic strategies primarily concentrate on reducing overall body weight and the burden of fat accumulation in the liver. However, the McMaster University findings strongly suggest that a more effective approach may involve a synergistic strategy.
“While current treatments predominantly focus on weight reduction and alleviating liver fat, our work presents compelling evidence for the significant value of integrating these approaches with therapies that directly target inflammation,” Professor Steinberg emphasized. “By unraveling the intricate mechanisms through which the body naturally defends its liver, we are better positioned to identify novel opportunities for developing more potent and effective treatments for individuals living with MASH.”
The study benefited from the collaborative efforts of Rune E. Kuhre and Sebastian B. Jørgensen from Novo Nordisk A/S. Funding for this critical research was provided by the Natural Sciences and Engineering Research Council of Canada (NSERC), the Canadian Institutes of Health Research (CIHR), and Diabetes Canada. Novo Nordisk also contributed research support and generously supplied the GDF15 hormone used in the experimental procedures.
The identification of this previously unrecognized signaling pathway mediated by GDF15 represents a significant leap forward in our understanding of liver health and disease. It underscores the complexity of hormonal signaling within the human body and highlights the potential for harnessing natural biological processes to combat chronic diseases. The scientific community eagerly anticipates how these findings will translate into tangible improvements in patient care and the development of next-generation therapies for MASH and related liver conditions.
